MIMICS & INHIBITORS,
CUSTOMER: miRagen Therapeautics, Inc
miRagen is focused on discovering and developing innovative microRNA-targeting therapies to improve human health, specifically in disease areas of: hematological malignancies, fibrosis, neuro-degeneration and cardiovascular disease.
microRNAs can be modulated by either decreasing the activity (inhibitors) or increasing the levels (mimics) of expressed microRNAs. These modulators can then directly affect the protein expression of the specific microRNA’s targets.